Pilulka Lékárny has completed an SPO on the START Market of the Prague Stock Exchange
June 2023 — Pilulka Lékárny, a.s. has completed an SPO on the START Market of the Prague Stock Exchange consisting of a capital increase through subscription of new shares. The funds will be used to further develop the company, particularly to strengthen its working capital, to bolster its activities in international markets and to further develop its own e-health solutions.
Since its foundation in 2013, Pilulka has emerged as a leading online pharmacy in central Europe and the operator of a network of franchise and select brick-and-mortar pharmacies in the Czech Republic. Pilulka operates in the Czech Republic, Slovakia and Romania, and entered the Austrian and Hungarian markets in 2022. Pilulka is the number one pharmacy e-shop in-home delivery in the Czech Republic and Slovakia, and among the top three retail pharmacy chains in the Czech Republic.
Our role in the transaction
Oaklins’ team in the Czech Republic acted as an SPO manager in this transaction. The team succeeded in attracting orders from retail investors and high-net-worth individuals.
Prata med transaktionsteamet
Relaterade transaktioner
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
Lär dig merTNT has been acquired by PM Studio
TNT Group has been acquired by PM Studio Group, backed by Andera Partners, bringing together two complementary specialists in premium packaging for the beauty and luxury industries. TNT’s expertise in bespoke primary packaging complements PM Studio’s secondary packaging, gifting and creative design capabilities, creating a broader, integrated offering for major luxury brands. The transaction strengthens the group’s geographical footprint in Asia and the USA, diversifying its customer portfolio. The combined group generates over US$145 million in revenue and has approximately 150 employees worldwide. Following the transition of operational leadership to CEO Damon Kennish, the founders completed the sale to PM Studio while making a significant reinvestment alongside the management team, demonstrating their confidence in the combined group’s long-term potential. It aims to reach US$280 million in revenue by 2029 through organic growth, commercial synergies and further acquisitions.
Lär dig merKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Lär dig mer